

AKEBIA COMPLIANCE				
CONNECTICUT DISCLOSURE INFORMATION				
Document Number: FRM 445	Effective: 1 October 2024	Version: 2.0		

AKEBIA THERAPEUTICS INC.

CONNECTICUT DISCLOSURE INFORMATION

I. PURPOSE

On June 27, 2023, Connecticut Governor Ned Lamont signed into law HB 6669, a bill that requires pharmaceutical manufacturers, like Akebia Therapeutics, Inc. (Akebia), to disclose certain information to Prescribers in the course of conducting business. Specifically, this information includes:

• The list price of prescription drugs manufactured.

This information is to be provided in writing to all Prescribers licensed in the state of Connecticut, that Akebia conducts business with.

II. WHOLESALE ACQUISITION COST

PRODUCT NAME	Manufacturer	NDC	PKG SIZE
Auryxia Oral Tablet 1 GM 210 MG(Fe)	KERYX BIOPHARMACEUTICALS ¹	59922-0631-01	200
		WAC / PACK	\$1548.00
		WAC / TAB	\$7.74

CONNECTICUT DISCLOSURE Page 1 of 1

¹ KERYX BIOPHARMACEUTICALS INC. IS A WHOLLY OWNED SUBSIDIARY OF AKEBIA THERAPEUTICS, INC.